Based on the most recent data, HIMS has returned 155.8% so far this year. Meanwhile, the Medical sector has returned an average of 6.8% on a year-to-date basis. This shows that Hims & Hers Health, Inc. is outperforming its peers so far this year. In TransMedics' case, the consensus EPS estimate for the current year increased 701.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Another stock in the Medical sector, TransMedics (TMDX) , has outperformed the sector so far this year. ...

Sustainability Projected Earnings Growth 90.00% Hims & Hers: A Story of Growth and Profitability Hims & Hers Health, Inc. (HIMS) Price Chart for Friday, July, 19, 2024 The company's foray into weight loss treatments, including the highly sought-after GLP-1 injections, further exemplifies its ability to adapt to market trends and capitalize on emerging opportunities. While GLP-1 is not the sole driver of Hims & Hers' investment thesis, it showcases the company's agility in integrating popular medications int ...

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. The most recent trading session ended with Hims & Hers Health, Inc. (HIMS) standing at $23.11, reflecting a +1. ...

Price is just one factor to consider. For other businesses, macro conditions remain challenging, and this has been reflected in their stock prices. All that said, if you're looking for intriguing stocks to buy that are trading at relatively meager valuations, there are some companies that could be compelling long-term investments. Here are two to consider as you add to your buy list. Hims & Hers (HIMS 3.18%) operates a health and wellness platform that lets users access telehealth services, prescriptions, a ...

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy). One other Medical stock that has outperformed the sector so far this year is Novo Nordisk (NVO) . The stock is up 37.6% year-to-date. In contrast, Novo Nordisk falls under the Large ...

There are valid points in the short report, but it may present a buying opportunity for long-term investors. Shares of Hims & Hers (HIMS 0.85%) fell on Thursday after a short report was published by a short-seller. This kind of report can often send stocks lower, but is it a reason to panic or a buying opportunity? In this video, Travis Hoium digs into the report's claims and why this is bullish for investors. *Stock prices used were end-of-day prices of June 27, 2024. The video was published on June 28, 20 ...

GLP-1 drugs for obesity and weight loss, which have shown to be extremely effective, are currently one of the most profitable and exciting trends in the market today. The market has been dominated by pharmaceutical giants Eli Lilly ((LLY) and Novo Nordisk ((NVO). However, I see significant opportunities for less mature companies like Hims & Hers Health to get involved. Hims & Hers Health (HIMS) already boasts a Zacks Rank #1 (Strong Buy) rating, reflecting the significant upward revisions to its earnings. H ...

Shares of online pharmacy Hims & Hers (HIMS -7.77%) dropped as much as 12.8% on Thursday after a shortseller wrote a report about the company. Shares recovered slightly during trading and are down 7.8% at 2:30 p.m. ET today. The short-seller's report In this case, Hunterbrook criticized Hims & Hers' GLP-1 weight-loss treatment, which is a compound made by a pharmacy and temporarily approved to fill shortages of GLP-1 drugs, and not a government-approved medication itself. There are questions, even by the Fo ...

Hims & Hers Health (NYSE:HIMS) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes research on stocks through Hunterbrook Media while sometimes taking a position in the same stock through its hedge fund affiliate, Hunterbrook Capital. In this instance, the hedge fund has disclosed that it is short HIMS stock. The premise of Hunterbrook's short report lies on Hims' compounded GLP-1 weight-loss ...

The company's stock has climbed by 31.22% in the past month, exceeding the Medical sector's gain of 0.61% and the S&P 500's gain of 2.73%. The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.05, marking a 266.67% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $297.53 million, up 43.1 ...